These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
99 related articles for article (PubMed ID: 7222188)
21. Dialyzability of the antiepileptic drug zonisamide in patients undergoing hemodialysis. Ijiri Y; Inoue T; Fukuda F; Suzuki K; Kobayashi T; Shibahara N; Takenaka H; Tanaka K Epilepsia; 2004 Aug; 45(8):924-7. PubMed ID: 15270757 [TBL] [Abstract][Full Text] [Related]
22. TNF-alpha: mRNA, plasma protein levels and soluble receptors in patients on chronic hemodialysis, on CAPD and with end-stage renal failure. van Riemsdijk-van Overbeeke IC; Baan CC; Hesse CJ; Loonen EH; Niesters HG; Zietse R; Weimar W Clin Nephrol; 2000 Feb; 53(2):115-23. PubMed ID: 10711413 [TBL] [Abstract][Full Text] [Related]
23. Decreased bioavailability of insulin-like growth factor-I, a cause of catabolism in hemodialysis patients? Lindgren BF; Odar-Cederlöf I; Ericsson F; Brismar K Growth Regul; 1996 Sep; 6(3):137-43. PubMed ID: 8894646 [TBL] [Abstract][Full Text] [Related]
24. The effect of mesna on plasma total homocysteine concentration in hemodialysis patients. Urquhart BL; Freeman DJ; Spence JD; House AA Am J Kidney Dis; 2007 Jan; 49(1):109-17. PubMed ID: 17185151 [TBL] [Abstract][Full Text] [Related]
25. Incidence and significance of rising blood acetate levels during hemodialysis. Mansell MA; Nunan TO; Laker MF; Boon NA; Wing AJ Clin Nephrol; 1979 Jul; 12(1):22-5. PubMed ID: 477053 [TBL] [Abstract][Full Text] [Related]
26. Prevalence of viremia in human immunodeficiency virus-infected patients with renal disease. Kimmel PL; VedBrat SS; Pierce PF; Umana WO; Shepherd L; Verme DA; Hirsch RP; Hellman KB Arch Intern Med; 1995 Aug 7-21; 155(15):1578-84. PubMed ID: 7618979 [TBL] [Abstract][Full Text] [Related]
27. Hyperhomocysteinemia and protein damage in chronic renal failure and kidney transplant pediatric patients--Italian initiative on uremic hyperhomocysteinemia (IIUH). Perna AF; Ingrosso D; Molino D; Galletti P; Montini G; Zacchello G; Bellantuono R; Caringella A; Fede C; Chimenz R; De Santo NG J Nephrol; 2003; 16(4):516-21. PubMed ID: 14696753 [TBL] [Abstract][Full Text] [Related]
29. Raised plasma total sialic acid levels are markers of cardiovascular disease in renal dialysis patients. Afzali B; Bakri RS; Bharma-Ariza P; Lumb PJ; Dalton N; Turner NC; Wierzbicki AS; Crook MA; Goldsmith DJ J Nephrol; 2003; 16(4):540-5. PubMed ID: 14696756 [TBL] [Abstract][Full Text] [Related]
30. Disposition of didanosine in HIV-seropositive patients with normal renal function or chronic renal failure: influence of hemodialysis and continuous ambulatory peritoneal dialysis. Knupp CA; Hak LJ; Coakley DF; Falk RJ; Wagner BE; Raasch RH; van der Horst CM; Kaul S; Barbhaiya RH; Dukes GE Clin Pharmacol Ther; 1996 Nov; 60(5):535-42. PubMed ID: 8941026 [TBL] [Abstract][Full Text] [Related]
31. Changes in plasma concentrations of hypoxanthine and uric acid before and after hemodialysis. Shahbazian H; Zand Moghadam A; Ehsanpour A; Khazaali M Iran J Kidney Dis; 2009 Jul; 3(3):151-5. PubMed ID: 19617664 [TBL] [Abstract][Full Text] [Related]
32. Circulating levels of adhesion molecules in chronic kidney disease correlate with the stage of renal disease and with C-reactive protein. Vaccaro F; Mulè G; Cottone S; Soresi M; Giannitrapani L; Vadalà A; Sparacino V; Calabrese S; Picone FP; Montalto G; Cerasola G Arch Med Res; 2007 Jul; 38(5):534-8. PubMed ID: 17560459 [TBL] [Abstract][Full Text] [Related]
33. Plasma levels of active and total ghrelin in renal failure: a relationship with GH/IGF-I axis. Jarkovská Z; Hodková M; Sazamová M; Rosická M; Dusilová-Sulková S; Marek J; Justová V; Lacinová Z; Haluzík M; Haas T; Krsek M Growth Horm IGF Res; 2005 Dec; 15(6):369-76. PubMed ID: 16198134 [TBL] [Abstract][Full Text] [Related]
34. Elevated homocysteine levels in patients with end-stage renal disease. Nair AP; Nemirovsky D; Kim M; Geer EB; Farkouh ME; Winston J; Halperin JL; Robbins MJ Mt Sinai J Med; 2005 Nov; 72(6):365-73. PubMed ID: 16358160 [TBL] [Abstract][Full Text] [Related]
35. Plasma protein aspartyl damage is increased in hemodialysis patients: studies on causes and consequences. Perna AF; Ingrosso D; Satta E; Lombardi C; Galletti P; D'Aniello A; De Santo NG J Am Soc Nephrol; 2004 Oct; 15(10):2747-54. PubMed ID: 15466280 [TBL] [Abstract][Full Text] [Related]
36. [Effect of damaged liver parenchyma, renal insufficiency and hemodialysis on the pharmacokinetics of cyclophosphamide and its activated metabolites]. Wagner T; Heydrich D; Bartels H; Hohorst HJ Arzneimittelforschung; 1980; 30(9):1588-92. PubMed ID: 7193030 [TBL] [Abstract][Full Text] [Related]
37. Plasma protein binding of drugs and adjustment of their dosing regimen in patients with chronic renal failure. Schück O Int J Clin Pharmacol Ther Toxicol; 1987 Sep; 25(9):476-8. PubMed ID: 3679618 [TBL] [Abstract][Full Text] [Related]